Financial Solutions for Healthcare & Life Sciences Startups
Key Takeaways
- Digital health, medtech, med device and life sciences companies have more financing options than most founders realize, and the right choice depends heavily on your stage, revenue model and development timeline.
- Healthcare and life sciences banking is a specialized discipline. The financing structures that work for a med device company mid-clinical trial look very different from those that work for a digital health platform with recurring revenue.
- Equity and debt aren’t mutually exclusive. Many high-growth healthcare tech companies use both; equity to fund long-horizon R&D and debt facilities to manage working capital and bridge between rounds.
- The best time to build a banking relationship is before you urgently need one. A lender who already understands FDA pathways, reimbursement models and life sciences capital structures can move faster and structure more thoughtfully when it matters.
Why healthcare and life sciences financing is its own conversation
Digital health, medtech, med device and life sciences companies operate in one of the most capital-intensive and regulatory-complex environments in business. Long development timelines, clinical milestones that shift, reimbursement uncertainty and revenue models that rarely follow a standard curve — all of it makes healthcare and life sciences finance a distinct discipline.
That complexity doesn’t make funding harder to find, but it does make knowing your options more important.
Funding options for healthcare tech and life sciences startups
Traditional bank financing:
Loans and lines of credit are a foundational tool for healthcare and life sciences companies, particularly those that have moved past early-stage development and can demonstrate revenue, a clear growth trajectory or a strong venture backing. Healthcare banking through a commercial lender typically involves working capital lines, term loans or equipment financing — structured around the company’s financial profile and borrowing needs. For medtech and med device companies, equipment financing can be particularly relevant given the capital intensity of hardware development and manufacturing. These facilities don’t require giving up equity, which matters for founders who want to preserve ownership while funding operations or a commercial launch.
Government grants and programs:
For companies focused on research, clinical innovation or underserved patient populations, government grants can be a meaningful source of non-dilutive capital. SBIR/STTR programs, NIH funding and various state-level initiatives specifically support innovation in digital health, life sciences and medical technology. The process is competitive and often slow, but the capital doesn’t cost equity, and a government award carries credibility that can support future fundraising conversations.
Venture capital:
VC funding is purpose-built for high-growth, high-risk companies, which describes a large portion of the digital health and life sciences landscape. In exchange for equity, venture capitalists provide capital and often bring sector expertise, clinical network access and a long-term interest in your company’s success. Healthcare-focused VCs understand clinical development timelines, regulatory pathways and the reimbursement landscape in ways that generalist investors may not. If you’re pursuing VC, look for investors with a track record in your specific vertical — digital health, medtech, med device or life sciences — not just “healthcare” broadly. The key consideration: VC is dilutive. Think carefully about how much equity you’re comfortable giving up and at what stage.
Angel investors and private equity:
Angel investors can be a good fit for earlier-stage companies that need both capital and strategic guidance; particularly in life sciences, where domain expertise from the right investor can open doors that capital alone can’t. Private equity tends to enter later, often backing companies with established revenue looking to scale, acquire or restructure. Both involve giving up some degree of ownership or control, and terms vary significantly. Understand what governance rights, board seats or reporting requirements come with any investment before committing.
How to choose the right healthcare finance strategy
There’s no universal answer, but a few useful filters:
- Where are you in your development? A pre-revenue medtech company working toward FDA clearance has different options than a digital health platform with signed health system contracts. Be honest about where you actually are.
- How much dilution are you willing to accept? Debt preserves ownership. Equity doesn’t. If you have the revenue and credit profile to support bank financing, it’s often worth exploring those options before opening another equity round.
- What does your capital actually need to do? R&D that won’t generate returns for several years is a different financing problem than working capital gaps between reimbursement cycles or a bridge ahead of a Series B. Match the instrument to the need.
- Do your potential partners understand the sector? A lender or investor who needs a primer on FDA approval timelines or Medicare reimbursement mechanics adds friction at exactly the wrong moment. In healthcare and life sciences finance, sector fluency isn’t a nice-to-have.
A team that knows this space
The Healthcare & Life Sciences practice within Customers Bank’s Tech & Venture team works specifically with venture-backed digital health, medtech, med device and life sciences companies. The bankers you work with understand how these businesses are structured — clinical milestones, investor backing, regulatory timelines and all — so the conversation starts at a different baseline.